Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
TransThera Sciences (Nanjing), Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05253053CT.gov To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04742959CT.gov Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gallbladder Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tinengotinib (this asset) | TransThera Sciences (Nanjing), Inc. | P1/2 | CCC · 55 |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | BBB |
| Capecitabine | Merck Sharp & Dohme LLC | P3 | BB |
| Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Sevoflurane | Tokyo Medical and Dental University | P4 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Epirubicin | Merck Sharp & Dohme LLC | P2 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | BB |
| Desflurane | Tokyo Medical and Dental University | P4 | BB |
+42 more in the Gallbladder Cancer cohort
Other indications for Tinengotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholangiocarcinoma | — | P3 | B · 59 |
| Triple-Negative Breast Carcinoma | — | P1/2 | B · 57 |
| Cancer | — | P1/2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tinengotinib in Gallbladder Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tinengotinib-gallbladder-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →